Zymeworks (ZYME) Catches Eye: Stock Jumps 7.7%
Zymeworks Inc. ZYME was a big mover last session, as the company saw its shares rise nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $34.18–$40.00 in the past one-month time frame, witnessed a sharp increase yesterday.
The company has seen three positive estimate revisions in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few months, suggesting that more solid trading could be ahead for Zymeworks. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Zymeworks currently has a Zacks Rank #2 (Buy) while its Earnings ESP is negative.
Zymeworks Inc. Price
Zymeworks Inc. price | Zymeworks Inc. Quote
Another stock worth considering in the Medical - Biomedical and Genetics industry is Akcea Therapeutics Inc AKCA which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Zymeworks Inc. (ZYME) : Free Stock Analysis Report
Akcea Therapeutics, Inc. (AKCA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
